Biogen Targets GSK's Cancer Drug Arzerra In IP Suit
Biogen Idec Inc. and Genentech Inc. have sued GlaxoSmithKline LLC, claiming the British pharmaceutical company's cancer treatment Arzerra infringes their newly issued patent for an antibody treatment for leukemia....To view the full article, register now.
Already a subscriber? Click here to view full article